Literature DB >> 2665169

Endothelial prostacyclin release in systemic lupus erythematosus.

S B Coade1, E van Haaren, S Loizou, M J Walport, A M Denman, J D Pearson.   

Abstract

The ability of sera from patients with SLE to stimulate endothelial cell prostacyclin production was studied using a standardized assay system for testing the effects of serum on cultured human endothelial cell monolayers. The effects of 20 normal and 32 SLE sera on endothelial prostacyclin production were measured. No differences between the rates of prostacyclin production were seen between the two groups, either basally or when prostacyclin release was stimulated with thrombin or bradykinin. In the SLE samples there was no correlation between anticardiolipin IgG or IgM titres and their ability to stimulate basal or agonist-induced prostacyclin release. These results suggest that the elevated risk of thrombosis in SLE patients is not associated with inhibition of endothelial cell prostacyclin synthesis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2665169

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  4 in total

Review 1.  Antiphospholipid syndrome: multiple mechanisms.

Authors:  C G Mackworth-Young
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

2.  Vascular damage in Wegener's granulomatosis and microscopic polyarteritis: presence of anti-endothelial cell antibodies and their relation to anti-neutrophil cytoplasm antibodies.

Authors:  C O Savage; B E Pottinger; G Gaskin; C M Lockwood; C D Pusey; J D Pearson
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

Review 3.  The 'antiphospholipid syndrome' and the 'lupus anticoagulant'.

Authors:  J S Cameron; G Frampton
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

4.  Inhibitory effects of anticardiolipin antibodies on lymphocyte proliferation and neutrophil phagocytosis.

Authors:  C L Yu; K H Sun; C Y Tsai; S R Wang
Journal:  Ann Rheum Dis       Date:  1991-12       Impact factor: 19.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.